EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and validation of a predictive model for severe radiation-induced esophagitis in lung cancer patients undergoing moderate hypofractionated radiotherapy

Entwicklung und Validierung eines Vorhersagemodells für schwere strahleninduzierte Ösophagitis bei Lungenkrebspatient:innen unter moderat hypofraktionierter Radiotherapie

Anqi Zhang, Mengjie Quan, WeiQian Li, Jing Cao, Yuee Liu, Bo Zhu, Xiaocang Ren, Yueliang Qin, Qiang Lin

Frontiers in Oncology · 03.10.2025 · 15

DOI: 10.3389/fonc.2025.1656907 ↗

Auf einen Blick

Bei 105 Lungenkrebspatient:innen unter moderat hypofraktionierter Radiotherapie sagte ein Modell schwere strahleninduzierte Ösophagitis mit moderater Trennschärfe voraus. Nach Korrektur sank die Diskrimination auf AUC 0,608.

Fragestellung

Lässt sich schwere strahleninduzierte Ösophagitis bei Lungenkrebspatient:innen unter moderat hypofraktionierter Radiotherapie mit klinischen und dosimetrischen Faktoren vorhersagen?

Methode

Entwicklung und interne Validierung eines prädiktiven Modells mit elastischer Netzregression und Firth-penalisierter logistischer Regression; fully nested bootstrap (B=1000); Bewertung mit ROC/AUC, Kalibrierung und DCA.

Ergebnisse

105 Patient:innen; Inzidenz von RIE Grad ≥3: 16,2 % (17/105). Finale Prädiktoren: mean GTV, V5, D2cc, zirkumferenzielle 2,6-Gy- und 3,0-Gy-Bestrahlungslänge. AUC korrigiert 0,608 (95 %-KI 0,464–0,761).

Einschränkungen

Optimismus-korrigierte Kalibrierungsparameter waren instabil, vermutlich wegen der begrenzten Zahl an Ereignissen.

Schlussfolgerung der Autor:innen

Mit elastischer Netzselektion und Firth-Regression wurde ein Modell zur Vorhersage schwerer RIE entwickelt. Es zeigte moderate Diskrimination und insgesamt akzeptable Kalibrierung und wurde als Nomogramm dargestellt.

Kernaussagen

  • RIE Grad ≥3 trat bei 16,2 % (17/105) auf
  • Korrigierte AUC: 0,608 (95 %-KI 0,464–0,761)
  • Nomogramm zur Risikostratifizierung und klinischen Anwendung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 03.10.2025. Verfasst von Anqi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Huabei Petroleum Administration Bureau General Hospital, Hebei Medical University, Renqiu, Hebei, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Moderate hypofractionated radiotherapy (MHRT) is an important treatment modality for lung cancer, offering shorter courses and improved local control, yet it also markedly increases the risk of severe radiation-induced esophagitis (RIE; grade ≥3). Severe RIE compromises quality of life and adherence to therapy and may necessitate interruption of radiotherapy. This study aimed to develop a prediction model based on clinical and dosimetric factors to identify high-risk patients receiving MHRT and to facilitate individualized treatment strategies.

Methods

Lung cancer patients receiving moderate hypofractionated radiotherapy were included, with the endpoint defined as grade ≥3 radiation-induced esophagitis. Baseline characteristics were summarized using non-missing data only. During model development, in each outer bootstrap training set, candidate variables underwent single-rule imputation (median for continuous variables, mode for categorical variables) and standardization, followed by variable selection via elastic-net regression and model building with Firth-penalized logistic regression; the outcome itself was not imputed. Fully nested bootstrap validation (B=1000) was performed to assess internal robustness, with optimism-corrected performance metrics and 95% confidence intervals reported. Discrimination was evaluated using ROC curves and AUC, calibration by calibration plots and the Hosmer–Lemeshow test, and clinical utility through decision curve analysis (DCA). The optimal threshold was determined by the Youden index, with the corresponding confusion matrix presented. Finally, a nomogram was constructed to facilitate clinical visualization and application.

Results

A total of 105 patients were included; the incidence of grade ≥3 RIE was 16.2% (17/105). Five predictors entered the final model via elastic-net selection: mean gross tumor volume (mean GTV), V5, D2cc, circumferential 2.6-Gy irradiated length, and circumferential 3.0-Gy irradiated length. The Firth-penalized logistic model showed good apparent performance: AUC=0.771, Brier score = 0.114, calibration slope = 1.16, and calibration intercept = 0.13. After optimism correction by fully nested bootstrap (B=1,000), discrimination decreased to AUC=0.608 (95% CI, 0.464–0.761) with a corresponding Brier score of 0.176 (95% CI, 0.114–0.247). The Hosmer–Lemeshow test yielded χ² = 7.84, p = 0.449, indicating acceptable overall fit. The Youden-index–derived optimal cutoff was 0.130, stratifying patients into high-risk (predicted probability ≥ 0.13) and lower-risk (< 0.13) groups. DCA demonstrated positive net benefit over “treat-all” and “treat-none” strategies across threshold probabilities of 0–0.8. Optimism-corrected calibration parameters were unstable, likely reflecting the limited number of events; these results should be interpreted with caution.

Conclusion

Using elastic-net feature selection and Firth logistic regression, we developed a model to predict severe (grade ≥3) RIE in lung cancer patients undergoing MHRT. The model exhibited moderate discriminatory ability with generally acceptable calibration, enables risk stratification and identification of high-risk patients, and is presented as a nomogram to support clinical application. It holds promise for guiding individualized radiotherapy decisions and the prevention of treatment-related complications.

Schlagwörter

Stichwörter der Autor:innen

elastic net regressionlung cancermoderate hypofractionated radiotherapypredictive modelradiation-induced esophagitis

Autor:innen und Institutionen

  • Oncology Department, Huabei Petroleum Administration Bureau General Hospital, Hebei Medical University, Renqiu, Hebei, China.
  • Anesthesiology Department, Huabei Petroleum Administration Bureau General Hospital, Hebei Medical University, Renqiu, Hebei, China.

Zitieren

APA

Zhang, A., Quan, M., Li, W., Cao, J., Liu, Y., Zhu, B., Ren, X., Qin, Y., & Lin, Q. (2025). Development and validation of a predictive model for severe radiation-induced esophagitis in lung cancer patients undergoing moderate hypofractionated radiotherapy. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1656907

Vancouver

Zhang A, Quan M, Li W, Cao J, Liu Y, Zhu B, et al. Development and validation of a predictive model for severe radiation-induced esophagitis in lung cancer patients undergoing moderate hypofractionated radiotherapy. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1656907

BibTeX
@article{Zhang2025,
  author = {Zhang, Anqi and Quan, Mengjie and Li, WeiQian and Cao, Jing and Liu, Yuee and Zhu, Bo and Ren, Xiaocang and Qin, Yueliang and Lin, Qiang},
  title = {Development and validation of a predictive model for severe radiation-induced esophagitis in lung cancer patients undergoing moderate hypofractionated radiotherapy},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1656907}
}
Kostenlos starten →